Q2 EPS Estimates for Globus Medical Raised by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Investment analysts at Zacks Research increased their Q2 2026 EPS estimates for Globus Medical in a research note issued to investors on Friday, May 22nd. Zacks Research analyst Team now expects that the medical device company will post earnings per share of $1.14 for the quarter, up from their previous estimate of $1.02. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Globus Medical’s Q3 2026 earnings at $1.15 EPS, Q4 2026 earnings at $1.32 EPS, Q1 2027 earnings at $1.11 EPS, Q2 2027 earnings at $1.18 EPS, FY2027 earnings at $4.73 EPS, Q1 2028 earnings at $1.28 EPS and FY2028 earnings at $5.31 EPS.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same period last year, the business earned $0.68 earnings per share. The business’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS.

GMED has been the subject of several other reports. Truist Financial set a $115.00 target price on shares of Globus Medical in a report on Wednesday, February 25th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Royal Bank Of Canada lifted their target price on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Barclays raised their price target on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Stock Performance

GMED stock opened at $84.84 on Monday. The firm has a 50 day moving average price of $87.26 and a 200-day moving average price of $87.99. Globus Medical has a 52-week low of $51.79 and a 52-week high of $101.40. The firm has a market capitalization of $11.52 billion, a price-to-earnings ratio of 19.73, a PEG ratio of 1.75 and a beta of 1.00.

Institutional Investors Weigh In On Globus Medical

Institutional investors and hedge funds have recently made changes to their positions in the company. Advisory Services Network LLC bought a new stake in shares of Globus Medical during the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC grew its position in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. SBI Securities Co. Ltd. grew its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the period. Parallel Advisors LLC grew its position in Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Globus Medical in the 3rd quarter worth approximately $36,000. Institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 18.38% of the stock is owned by company insiders.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.